The purpose of the prospective, open, randomized controlled, multicenter, exploratory clinical study is to evaluate efficacy and safety of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
Histologically or cytologically confi rmed pancreatic cancer;
ECOG performance no more than 1;
Radiographically assessed as locally advanced pancreatic cancer according ;
No previous anti-tumor therapy;
Prior anti-tumor therapy of any kind;
Known to be symptomatic central nervous system metastasis and/or cancerous meningitis.
Patients with autoimmune disease or immune deficiency who are treated with immuno-suppressive drugs;
Patients with bleeding tendency;
Parallel
Nal-lRl+Oxaliplain+5- FU +PD 1
DrugNal-lRl+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
Nal-lRl+Oxaliplain+5- FU
DrugNal-lRl+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
1 year OS rate
Proportion of patients alive from randomization to 1 year
R0/R1 rate
Percentage of patients who achieved R0/RI resection
The rate of mPR
Proportion of patients who achieved mPR by post-operative specimen testing
OS
Time from randomization to death
ORR
According to RECIST version 1.1, the proportion of patients who achieved remission (PR+CR) after treatment and maintained the minimum time-frame requirement.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
